scholarly journals Combination Therapy of Alpha-Glucosidase Inhibitor, Thiazolidinedione and Sodium Glucose Co-Transporter-2 Inhibitor in Japanese Type 2 Diabetes Patients

2020 ◽  
Vol 10 (6) ◽  
pp. 167-172
Author(s):  
Masataka Kusunoki ◽  
Naomi Wakazono ◽  
Kazuhiko Tsutsumi ◽  
Yoshiharu Oshida ◽  
Tesuro Miyata
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Glucosidase Inhibitor ◽  
Alpha Glucosidase ◽  
Diabetes Patients

scholarly journals DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes (EDGE study)

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P1432-P1432
Author(s):  
H. Kihara ◽  
K. Nakamura ◽  
H. Oe ◽  
K. Shimada ◽  
S. Fukuda ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Endothelial Function ◽  
Glucosidase Inhibitor ◽  
Alpha Glucosidase

scholarly journals DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

2014 ◽  
Vol 13 (1) ◽  
Author(s):  
Kazufumi Nakamura ◽  
Hiroki Oe ◽  
Hajime Kihara ◽  
Kenei Shimada ◽  
Shota Fukuda ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Endothelial Function ◽  
Glucosidase Inhibitor ◽  
Alpha Glucosidase

The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors

2020 ◽  
Vol 20 ◽  
Author(s):  
Masataka Kusunoki ◽  
Takahiko Sakazaki ◽  
Kazuhiko Tsutsumi ◽  
Tetsuro Miyata ◽  
Yoshiharu Oshida
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Hepatic Dysfunction ◽  
Combination Group ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Diabetes Patients

Objective: The combination therapy of HMG-CoA reductase inhibitors (statins), which are anti-hyperlipidemia agents, and fibrates may increase the risk of hepatic dysfunction and myopathy, so this combination required careful administration for patients. In the present study, we evaluated the effects of combination therapy of pemafibrate, a novel fibrate and statins. Methods: We administered pemafibrate for 6 months as an add-on to statin therapy in 27 type 2 diabetes patients with dyslipidemia already receiving statins for 6 months (combination group), and examined the efficacy and safety of the combination therapy in comparison with a pemafibrate monotherapy group. Results: In the combination group, decrease in serum total cholesterol levels was observed after 6 months of pemafibrate treatment compared to baseline, along with increase in HDL-cholesterol. While serum triglyceride level reduced, HbA1c level was elevated in both the groups. Serum creatinine kinase level, which is an indicator of myopathy, was lowered in the combination group. In addition, decrease in -glutamyl transpeptidase, a parameter of hepatic dysfunction, was observed in the combination group. Conclusion: The statin-pemafibrate combination therapy in type 2 diabetes patients with dyslipidemia improved lipid metabolism safely without increasing the risk of hepatic dysfunction and myopathy.

scholarly journals Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide

2013 ◽  
Vol 5 (4) ◽  
pp. 400-409 ◽  
Author(s):  
Kyoko Kudo-Fujimaki ◽  
Takahisa Hirose ◽  
Tomoaki Yoshihara ◽  
Fumihiko Sato ◽  
Yuki Someya ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Efficacy And Safety ◽  
Diabetes Patients

scholarly journals Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

2012 ◽  
Vol 3 (6) ◽  
pp. 503-509 ◽  
Author(s):  
Akira Kubota ◽  
Hajime Maeda ◽  
Akira Kanamori ◽  
Kiyokazu Matoba ◽  
Yasuyuki Jin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Efficacy And Safety ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document